Mycobacterium tuberculosis (M. tb) has led to approximately 1.3 million deaths globally in
2020 according to the World Health Organization (WHO). More effective treatments are …

An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

Tuberculosis is a major health concern. Non-living tuberculosis (TB) vaccine candidates
may not only be safer than the current vaccine (BCG) but could also be used to boost BCG to …

Here, we report on a first-in-man trial where the tuberculosis (TB) vaccine Ag85B-ESAT-6
(H1) was adjuvanted with escalating doses of a novel liposome adjuvant CAF01. On their …

With over eight million cases of tuberculosis each year there is a pressing need for the
development of new vaccines against Mycobacterium tuberculosis. Subunit vaccines …

Mycobacterium tuberculosis HN878 represents a virulent clinical strain from the W-Beijing
family, which has been tested in small animal models in order to study its virulence and its …

Background. Recent advances in rational adjuvant design and antigen selection have
enabled a new generation of vaccines with potential to treat and prevent infectious disease …

It is estimated that one third of the world's population is infected with Mycobacterium
tuberculosis (Mtb). This astounding statistic, in combination with costly and lengthy treatment …

Considerable effort has been directed to develop Mycobacterium tuberculosis vaccines to
boost bacille Calmette-Guérin or for those who cannot be immunized with bacille Calmette …

Tuberculosis (TB) has been and still is a global emergency for centuries. Prevention of
disease through vaccination would have a major impact on disease prevalence, but the only …